Valeo Pharma Inc. VP2.F Stock
Valeo Pharma Inc. Price Chart
Valeo Pharma Inc. VP2.F Financial and Trading Overview
Valeo Pharma Inc. stock price | 0.04 EUR |
Previous Close | 0.24 EUR |
Open | 0.25 EUR |
Bid | 0.25 EUR x N/A |
Ask | 0.3 EUR x N/A |
Day's Range | 0.25 - 0.25 EUR |
52 Week Range | 0.21 - 0.51 EUR |
Volume | 13K EUR |
Avg. Volume | 0 EUR |
Market Cap | 22.66M EUR |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.22 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
VP2.F Valuation Measures
Enterprise Value | 72.96M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.49847782 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 1.605 |
Enterprise Value/EBITDA | -5.75 |
Trading Information
Valeo Pharma Inc. Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | -39.49% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.51 EUR |
52 Week Low | 0.21 EUR |
50-Day Moving Average | 0.28 EUR |
200-Day Moving Average | 0.37 EUR |
VP2.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 82.27M |
Float | 34.12M |
Short Ratio | N/A |
% Held by Insiders | 49.46% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | October 31, 2022 |
Most Recent Quarter (mrq) | April 30, 2023 |
Next Fiscal Year End | October 31, 2023 |
Profitability
Profit Margin | -60.32% |
Operating Margin (ttm) | -32.029% |
Gross Margin | 29.97% |
EBITDA Margin | -27.91% |
Management Effectiveness
Return on Assets (ttm) | -25.0060% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 45.46M EUR |
Revenue Per Share (ttm) | 0.55 EUR |
Quarterly Revenue Growth (yoy) | 184.40% |
Gross Profit (ttm) | 8.52M EUR |
EBITDA | -12688000 EUR |
Net Income Avi to Common (ttm) | -27421000 EUR |
Diluted EPS (ttm) | -0.26 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 10.12M EUR |
Total Cash Per Share (mrq) | 0.12 EUR |
Total Debt (mrq) | 62.81M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 2.15 |
Book Value Per Share (mrq) | -0.348 |
Cash Flow Statement
Operating Cash Flow (ttm) | -25021000 EUR |
Levered Free Cash Flow (ttm) | -20505624 EUR |
Profile of Valeo Pharma Inc.
Country | Germany |
State | QC |
City | Kirkland |
Address | 16667 Hymus Boulevard |
ZIP | H9H 4R9 |
Phone | 514-694-0150 |
Website | https://www.valeopharma.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 115 |
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. In addition, the company provides Ametop Gel 4%, for skin anesthesia prior to injection or cannulation; Sabizabulin, oral dual antiviral/anti-inflammatory agent for high-risk hospitalized adults suffering from covid-19; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, an prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory / allergy, ophthalmology, and specialty and hospital generic products. Valeo Pharma Inc. was incorporated in 2003 and is headquartered in Kirkland, Canada.
Q&A For Valeo Pharma Inc. Stock
What is a current VP2.F stock price?
Valeo Pharma Inc. VP2.F stock price today per share is 0.04 EUR.
How to purchase Valeo Pharma Inc. stock?
You can buy VP2.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Valeo Pharma Inc.?
The stock symbol or ticker of Valeo Pharma Inc. is VP2.F.
Which industry does the Valeo Pharma Inc. company belong to?
The Valeo Pharma Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Valeo Pharma Inc. have in circulation?
The max supply of Valeo Pharma Inc. shares is 157.21M.
What is Valeo Pharma Inc. Price to Earnings Ratio (PE Ratio)?
Valeo Pharma Inc. PE Ratio is now.
What was Valeo Pharma Inc. earnings per share over the trailing 12 months (TTM)?
Valeo Pharma Inc. EPS is -0.22 EUR over the trailing 12 months.
Which sector does the Valeo Pharma Inc. company belong to?
The Valeo Pharma Inc. sector is Healthcare.